News
HOOK
0.8041
+5.80%
0.0441
Roche's Lymphoma Drug With Chemo Extends Survival In Pretreated Patients
Roche announced topline data from Phase 3 STARGLO study of Columvi in certain subset of patients with diffuse large B-cell lymphoma. Earlier this year, Roche terminated two cancer drug deals. The drug is the first fixed-duration antibody to receive FDA accelerated approval.
Benzinga · 1d ago
Weekly Report: what happened at HOOK last week (0408-0412)?
Weekly Report · 1d ago
HOOKIPA PHARMA INC: EMA HAS GRANTED PRIME DESIGNATION FOR INVESTIGATIONAL PRODUCT HB-200 IN COMBINATION WITH PEMBROLIZUMAB
Reuters · 6d ago
HOOKIPA Pharma to Host Investor Call on HB-200 and Planned Path to Registration
HOOKIPA Pharma Inc. Is a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform. The investor call will be held on April 25, 2024, at 8:00 a.m. ET. The company and the FDA have aligned on the design and protocol of HB-200's upcoming pivotal clinical trial.
Barchart · 6d ago
Weekly Report: what happened at HOOK last week (0401-0405)?
Weekly Report · 04/08 09:25
Weekly Report: what happened at HOOK last week (0325-0329)?
Weekly Report · 04/01 09:25
Optimistic Buy Rating for Hookipa Pharma Based on Promising HB-200 Trial Results and Strategic Trial Design
TipRanks · 03/27 06:56
HOOKIPA Pharma Price Target Maintained With a $5.00/Share by RBC Capital
Dow Jones · 03/25 14:30
RBC Capital Reiterates Outperform on HOOKIPA Pharma, Maintains $5 Price Target
Benzinga · 03/25 14:25
HOOKIPA Pharma Price Target Maintained With a $6.50/Share by HC Wainwright & Co.
Dow Jones · 03/25 10:35
Analysts Offer Insights on Healthcare Companies: Rockwell Med (RMTI), Hookipa Pharma (HOOK) and Sagimet Biosciences, Inc. Class A (SGMT)
TipRanks · 03/25 10:30
HC Wainwright & Co. Reiterates Buy on HOOKIPA Pharma, Maintains $6.5 Price Target
Benzinga · 03/25 10:25
Weekly Report: what happened at HOOK last week (0318-0322)?
Weekly Report · 03/25 09:26
Hookipa Pharma (HOOK) Receives a Buy from RBC Capital
In a report released on March 22, Brian Abrahams from RBC Capital maintained a Buy rating on Hookipa Pharma (HOOK – Research Report), with a price target of $5.00. The company’s shares closed last Friday at $0.71. The Street suggests a Strong Buy analyst consensus rating for HookipA Pharma with a $4.67 average price target. Hookip a Pharma is developing immunotherapeutics targeting infectious diseases and cancers.
TipRanks · 03/25 01:48
BUZZ-U.S. STOCKS ON THE MOVE-Reddit, Alphabet, Tesla
The blue-chip Dow and the benchmark S&P 500 eased on Friday, but are still on track for strong weekly gains. Investors cheered the Federal Reserve's rate-easing stance. Reddit, Alphabet and Tesla were among the biggest losers on Wall Street. The Dow Jones Industrial Average was down 0.46% and the Nasdaq Composite was up.
Reuters · 03/22 17:59
HOOK Stock Earnings: HOOKIPA Pharma Misses EPS, Beats Revenue for Q4 2023
HOOKIPA Pharma reported earnings per share of -22 cents for the fourth quarter of 2023. The company reported revenue of $7.41 million. This was 62.79% better than the analyst estimate for revenue of -18 cents. HOOKIPa Pharma just reported results for fourth quarter.
Investorplace · 03/22 17:52
Buy Rating Affirmed for Hookipa Pharma on Emerging Oncology and Infectious Disease Pipelines
Roy Buchanan, an analyst from JMP Securities, reiterated the Buy rating on Hookipa Pharma (HOOK) The associated price target is $5.00. The company is a leader in the development of immunotherapeutics for head and neck cancer. The analyst believes the company’s innovative arenavirus platform has the potential to generate superior CD8+ responses.
TipRanks · 03/22 15:55
HOOKIPA Pharma: Q4 Earnings Insights
HOOKIPA Pharma reported its Q4 earnings on March 22, 2024. The company missed its earnings estimate by 16.0%. HOOKIPa Pharma's revenue was down $421 thousand from the same period last year. Last quarter the company beat on EPS by $0.04.
Benzinga · 03/22 13:20
BUZZ-U.S. STOCKS ON THE MOVE-Hookipa Pharma, Foot Locker, Baidu
S&P 500 and the Nasdaq were set to open lower on Friday after strong gains in the previous session. Investors cheered the Federal Reserve sticking to its rate-easing stance. Hookipa Pharma, Foot Locker, Baidu are among the top stocks on the U.S. Market.
Reuters · 03/22 13:14
BUZZ-Hookipa Pharma rises after posting higher full-year revenue
Shares of therapy developer Hookipa Pharma rise 4.9% to 76 cents premarket. Company's revenue for 12 months ended Dec. 31 at $20.1 million. Company posted higher full-year revenue than a year ago. Company has cash and cash equivalents of $117 million.
Reuters · 03/22 12:23
More
Webull provides a variety of real-time HOOK stock news. You can receive the latest news about Hookipa Pharma through multiple platforms. This information may help you make smarter investment decisions.
About HOOK
HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel immunotherapies, based on its proprietary arenavirus platform, which is designed to mobilize and amplify targeted T cells and thereby fight or prevent serious disease. The Company’s replicating and non-replicating technologies are engineered to induce durable antigen-specific CD8+ T cell responses and pathogen-neutralizing antibodies. Its oncology programs include HB-200 and HB-700, all of which use its replicating technology. HB-200 is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) cancers in a Phase I/II clinical trial. HB-700 is in preclinical development for the treatment of KRAS mutated cancers, including lung, colorectal and pancreatic cancers. Its Hepatitis B (HBV) program, HB-400, and its Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in a partnership with Gilead Sciences, Inc.